Abstract Details

Title Memory Screening for aMCI and Dementia in Latinos

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 144

Objective

Background BACKGROUND: Identifying aMCI and very mild dementia in primary care settings will become increasingly important as new treatments emerge. The pFCSRT-IR has demonstrated utility in low education and African American samples but has not been tested in Latinos.

Design/Methods DESIGN/METHODS: We administered a Spanish or English language version of the pFCSRT-IR to 117 patients over the age of 65 seen in an urban primary care clinic. Follow-up diagnostic evaluations including neuropsychological testing and informant interviews were used to assign an independent consensus clinical diagnosis of no memory impairment, aMCI or dementia using standard criteria. We assessed the validity of an empirical cut-score of 24 on the pFCSRT-IR for distinguishing the aMCI/dementia group from the no memory impairment group and explored the effects of education.

Results RESULTS: Of the 117 patients, 47 were Latino (mean age =73, %F= 66). The Latino patients chose to be tested in Spanish (64%) or English (36%). 70 patients were non-Latinos (Mean age =75, %F= 80) and tested in English. A total of 43 participants had aMCI or dementia. Using clinical diagnosis as the gold standard, the pFCSRT-IR has excellent validity as screen for aMCI/dementia both in Latinos (72% sensitivity; 83% specificity) and non-Latinos (76% sensitivity; 87% specificity). Empirical exploration of alternative cut-scores and adjustment for education did not materially improve results.

Conclusions CONCLUSIONS: These results suggest that the pFCSRT-IR is effective as a screening test for aMCI/dementia in Latino and non-Latino urban samples and that cut-scores do not require adjustment either for language or education.

Authors/Disclosures
Ellen H. Grober, PhD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
Christian Bien, MD (Epilepsy Centre Bethel)	Dr. Bien has nothing to disclose.

��ɫ��

��ɫ��